#1 Clinical Trials Search in Europe

Telisotuzumab Vedotin

Telisotuzumab Vedotin, also known as ABBV-399, is an investigational drug being studied in clinical trials for the treatment of non-small cell lung cancer (NSCLC). This article explores the ongoing research on Telisotuzumab Vedotin, its potential benefits, and its role in addressing specific types of NSCLC, particularly those overexpressing the c-Met protein. The trials aim to assess the drug’s safety, efficacy, and potential combinations with other treatments to improve outcomes for patients with advanced NSCLC.

Table of Contents

What is Telisotuzumab Vedotin?

Telisotuzumab Vedotin, also known as ABBV-399, is an investigational drug being developed for the treatment of non-small cell lung cancer (NSCLC)[1]. It belongs to a class of drugs called antibody-drug conjugates, which are designed to target and kill cancer cells more precisely than traditional chemotherapy[4].

How Does It Work?

Telisotuzumab Vedotin works by targeting a specific protein called c-Met, which is often overexpressed in certain types of lung cancer. The drug consists of two main parts:

  • An antibody that recognizes and binds to c-Met on cancer cells
  • A potent anti-cancer drug (vedotin) attached to the antibody

When Telisotuzumab Vedotin binds to c-Met on cancer cells, it delivers the vedotin directly to these cells, potentially killing them while minimizing damage to healthy cells[2].

What Conditions Does It Treat?

Telisotuzumab Vedotin is primarily being studied for the treatment of non-small cell lung cancer (NSCLC). Specifically, it is being investigated for patients with:

  • Advanced or metastatic NSCLC (cancer that has spread to other parts of the body)
  • NSCLC that overexpresses the c-Met protein
  • NSCLC that has a mutation in the epidermal growth factor receptor (EGFR) gene
  • NSCLC that has progressed after previous treatments

Some studies are also exploring its use in other advanced solid tumors that express c-Met[5][4].

Current Research and Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of Telisotuzumab Vedotin:

  • Phase 2 studies are assessing its use as a single agent in previously treated NSCLC patients[2].
  • A Phase 3 study is comparing Telisotuzumab Vedotin combined with osimertinib (another lung cancer drug) to standard chemotherapy in patients with EGFR-mutant, c-Met overexpressing NSCLC[5].
  • Other studies are exploring different dosing regimens and combinations with other cancer drugs[4].

These trials aim to determine the optimal use of Telisotuzumab Vedotin and identify which patients are most likely to benefit from the treatment.

Administration and Dosing

Telisotuzumab Vedotin is administered as an intravenous (IV) infusion, which means it is given directly into a vein. The dosing schedule varies depending on the specific clinical trial, but some common regimens include:

  • Every 14 days (2 weeks) on a 28-day cycle[1]
  • Every 21 days (3 weeks)[4]

The exact dose and schedule may be adjusted based on how well a patient tolerates the treatment and their individual response.

Potential Side Effects

As with any cancer treatment, Telisotuzumab Vedotin may cause side effects. Some potential side effects being monitored in clinical trials include:

  • Interstitial lung disease (ILD): A group of lung disorders that can cause inflammation and scarring of lung tissue
  • Peripheral neuropathy: Numbness, tingling, or pain in the hands and feet
  • Ocular surface disorders: Problems affecting the surface of the eye
  • Other general side effects such as fatigue, nausea, or changes in blood cell counts

It’s important to note that not all patients will experience these side effects, and researchers are carefully monitoring patients to understand the safety profile of the drug[1].

Future Prospects

Telisotuzumab Vedotin shows promise as a potential new treatment option for certain types of non-small cell lung cancer, particularly those that overexpress the c-Met protein. Ongoing research aims to:

  • Determine its effectiveness compared to standard treatments
  • Identify which patients are most likely to benefit from the drug
  • Explore combinations with other cancer therapies to potentially improve outcomes

While Telisotuzumab Vedotin is still considered an investigational drug, early results have been encouraging enough to warrant further study. Patients interested in learning more about this treatment should discuss it with their oncologist to see if they might be eligible for any ongoing clinical trials[3].

Aspect Details
Drug Name Telisotuzumab Vedotin (ABBV-399)
Type of Cancer Non-Small Cell Lung Cancer (NSCLC)
Target Population Patients with c-Met overexpressing NSCLC, including those with EGFR mutations
Administration Intravenous (IV) infusion
Trial Phases Phase 1, 2, and 3 studies ongoing
Key Objectives Safety, efficacy, pharmacokinetics, progression-free survival, overall survival
Combination Therapies Studied with osimertinib, erlotinib, nivolumab, and standard chemotherapy
Primary Outcomes Adverse events, response rates, progression-free survival
Secondary Outcomes Duration of response, disease control rate, overall survival, quality of life measures
Special Considerations Monitoring for interstitial lung disease, peripheral neuropathy, ocular surface disorders

FAQ

  • What is Telisotuzumab Vedotin? Telisotuzumab Vedotin, also known as ABBV-399, is an investigational drug being developed for the treatment of non-small cell lung cancer (NSCLC). It is administered through intravenous infusion and is designed to target tumors that overexpress the c-Met protein.
  • What types of NSCLC is Telisotuzumab Vedotin being studied for? Telisotuzumab Vedotin is being studied for various types of NSCLC, including those with c-Met overexpression, EGFR mutations, and in patients who have previously been treated with other therapies. It is being investigated in both locally advanced and metastatic NSCLC cases.
  • How is Telisotuzumab Vedotin administered in clinical trials? In clinical trials, Telisotuzumab Vedotin is typically administered as an intravenous (IV) infusion. The dosing schedule varies between trials, with some administering it every 14 days or in 21-day or 28-day cycles, depending on the specific study design.
  • What are the main objectives of the clinical trials involving Telisotuzumab Vedotin? The main objectives of these clinical trials include assessing the safety and efficacy of Telisotuzumab Vedotin, determining the appropriate dosage, evaluating its effects on disease progression and overall survival, and exploring its potential in combination with other treatments such as osimertinib or standard chemotherapy.
  • Are there any known side effects of Telisotuzumab Vedotin? As with any investigational drug, the full side effect profile is still being studied. Clinical trials are monitoring for adverse events, which may include general side effects associated with cancer treatments. Specific side effects being closely watched include interstitial lung disease, peripheral neuropathy, and ocular surface disorders.

Ongoing Clinical Trials on Telisotuzumab Vedotin

  • Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Study on the Safety and Effectiveness of Telisotuzumab Vedotin for Patients with Previously Treated c-Met Positive Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Ireland Italy +2

  • Study of Telisotuzumab Vedotin for Adults with Advanced Non-Squamous Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1
    Investigated drugs:
    France Germany Italy Romania Spain

Glossary

  • Non-Small Cell Lung Cancer (NSCLC): A type of lung cancer that forms in the tissues of the lung. It is the most common type of lung cancer and includes several subtypes.
  • c-Met: A protein that, when overexpressed in cancer cells, can contribute to tumor growth and spread. Some NSCLC tumors overexpress c-Met, making it a target for certain cancer therapies.
  • Telisotuzumab Vedotin: An investigational drug (also known as ABBV-399) being developed for the treatment of NSCLC, particularly in tumors that overexpress the c-Met protein.
  • EGFR: Epidermal Growth Factor Receptor, a protein that plays a role in cell growth. Mutations in the EGFR gene can lead to uncontrolled cell division in some lung cancers.
  • Intravenous (IV) Infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Response Evaluation Criteria in Solid Tumors (RECIST): A standard way to measure how well a cancer patient responds to treatment, based on whether tumors shrink, stay the same, or get bigger.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.

References

  1. https://clinicaltrials.gov/study/NCT06568939
  2. https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-telisotuzumab-vedotin-for-patients-with-previously-treated-c-met-positive-non-small-cell-lung-cancer/
  3. https://clinicaltrials.gov/study/NCT04830202
  4. https://clinicaltrials.gov/study/NCT02099058
  5. https://clinicaltrials.gov/study/NCT06093503